Compass Therapeutics to Present at the 2022 H.C. Wainwright Annual Global Investment Conference
Compass Therapeutics, a clinical-stage biopharmaceutical company focused on antibody-based cancer treatments, announced that CEO Thomas J. Schuetz will present at the 2022 H.C. Wainwright Global Investment Conference from May 23-26, 2022. The webinar will be available on-demand starting May 24, 2022, at 7:00 a.m. ET, and can be accessed through their website. Compass Therapeutics is dedicated to developing therapies targeting angiogenesis and immune response mechanisms to combat tumors, with a pipeline aimed at advancing multiple product candidates.
- None.
- None.
BOSTON, May 23, 2022 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage biopharmaceutical company developing proprietary antibody-based therapeutics to treat cancer, today announced Thomas J. Schuetz, M.D., Ph.D., Co-founder and Chief Executive Officer, is presenting virtually at the 2022 H.C. Wainwright Global Investment Conference, occurring May 23-26th, 2022.
Webinar Details:
| Date: | On demand May 24, 2022 |
| Time: | 7:00 a.m. ET, May 24 through May 26, 2022 |
| Webcast: | https://journey.ct.events/view/75350822-64ee-48aa-b426-0b9912b526f2 |
| Virtual/Replay availability: | The presentation will be archived for 90 days on https://www.compasstherapeutics.com |
About Compass Therapeutics
Compass Therapeutics, Inc. is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. Compass’s scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. The company pipeline of novel product candidates is designed to target multiple critical biological pathways required for an effective anti-tumor response. These include modulation of the microvasculature via angiogenesis-targeted agents, induction of a potent immune response via activators on effector cells in the tumor microenvironment, and alleviation of immunosuppressive mechanisms used by tumors to evade immune surveillance. Compass plans to advance its product candidates through clinical development as both standalone therapies and in combination with proprietary pipeline antibodies based on supportive clinical and nonclinical data. The company was founded in 2014 and is headquartered in Boston, Massachusetts. For more information, visit the Compass Therapeutics website at https://www.compasstherapeutics.com.
Forward-Looking Statements
This press release contains forward-looking statements. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to the Company’s financial position to continue advancing its product candidates, expectations about the Company’s cash runway, business and development plans, and statements regarding the Company’s product candidates, their development, regulatory plans with respect thereto and therapeutic potential thereof, planned interactions with regulatory authorities, and planned clinical development. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the Company’s ability to raise the additional funding it will need to continue to pursue its business and product development plans, the inherent uncertainties associated with developing product candidates and operating as a development stage company, the Company’s ability to identify additional product candidates for development, the Company’s ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates, competition in the industry in which the Company operates and market conditions. These forward-looking statements are made as of the date of this press release, and the Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the SEC available at www.sec.gov, including without limitation our Form 10-K for the year ended December 31, 2021, and our subsequent filings with the SEC.
Investor Contact
Vered Bisker-Leib, President & Chief Operating Officer
ir@compasstherapeutics.com
Media Contact
Anna Gifford, Communications Manager
media@compasstherapeutics.com
617-500-8099
FAQ
What is the date of Thomas J. Schuetz's presentation at the 2022 H.C. Wainwright Global Investment Conference?
How can I access the Compass Therapeutics presentation from the conference?
Where is Compass Therapeutics headquartered?
What are the main focuses of Compass Therapeutics in cancer treatment?
What is the stock symbol for Compass Therapeutics?
